Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases

• Main Authors: Rocco Spagnuolo, Tiziana Montalcini, Daniele De Bonis, Yvelise Ferro, Cristina Cosco, Elisa Mazza, Stefano Romeo, Patrizia Doldo, Arturo Pujia
• Format: Article
• Language: English
• Published: MDPI AG 2019-02-01
• Series: Nutrients
• Subjects: inflammatory bowel diseases; weight gain; hepatic steatosis; transient elastography
• Online Access: https://www.mdpi.com/2072-6643/11/2/303

Background and Aim: Most studies focused on the benefits of weight loss on hepatic steatosis and no studies have been specifically designed to assess the role of weight gain on the development of liver steatosis in patients affected by inflammatory bowel diseases. The aim of this study was to analyse the relation between weight change over time and liver steatosis in patients with inflammatory bowel diseases. Methods: We retrospectively evaluated a population of 89 ambulatory patients in clinical remission or affected by mild disease, as determined from disease activity indices, with at least one follow-up visit. Transient elastography was used to quantify liver steatosis. Results: A total of 49 individuals (55%) were overweight/obese at baseline. A significant difference in weight change was found between participants that improved, were stable and worsened, over a mean follow-up of four years. (&#8722;1.0 kg &#177; 4; 2.5 kg &#177; 6; and 5.4 kg &#177; 5; respectively, <i>p</i> = 0.009). We found a greater probability of worsening in the hepatic fat content in individuals who gained more than 6% of body weight than in those gaining less than this value (log&#8315;rank (Mantel&#8315;Cox) &#967;² test = 9.85; df = 1; <i>p</i> = 0.002). Conclusions: A body weight gain of 6% increases the probability of deterioration in liver steatosis over a period of four years in patients with inflammatory bowel diseases. Weight gain prevention with lifestyle interventions may be the cornerstone treatment of these patients.